Treatment with DEX improves pulmonary compliance in premature infants with chronic lung disease but can impair normal growth and bone development. We investigated whether adjunctive therapy with GH or GH+IGF-I during DEX could attenuate the detrimental effects of DEX. Seven day old male piglets (n=32) were randomized to placebo control, DEX (oral dose 0.5, 0.3 and 0.2 mg/kg/d for 5 d each), DEX+GH (0.1 mg/kg/d) or DEX+GH+IGF-I (0.1 mg/kg/d). Weight was measured daily. Blood samples and length were taken at each change in DEX dose. Whole body and femoral bone mineral density (HMD) were measured at d 15 using dual energy x-ray absorptiometry (Hologic QDR1000W). At d 15, the DEX+GH and DEX+GH+IGF-I groups were significantly (p<0.05) heavier and longer than DEX alone. Plasma GH was not altered by any treatment. Plasma IGF-I was lowest in DEX piglets but infusion of IGF-I resulted in significantly (p<0.05) higher IGF-I compared to all other groups at d 15. DEX reduced (p<0.05) circulating IGFBP-3 on d 11, and IGFBP-2 on d 6, 11 and 15 compared to control. Plasma osteocalcin was reduced (p<0.05) by DEX alone at d 6 and d 11 compared to control but by d 11 there was a rise to higher (p<0.05) values in DEX+GH and DEX+GH+IGF-I vs DEX alone. The lower (p<0.05) whole body and femoral BMD in DEX vs control was not observed in piglets treated with DEX+GH or DEX+GH+IGF-I. The results indicate that GH promotes normalization of growth and bone metabolism during DEX therapy; no synergistic effect of IGFI with GH was observed.
|Original language||English (US)|
|State||Published - 1996|
ASJC Scopus subject areas
- Agricultural and Biological Sciences (miscellaneous)
- Biochemistry, Genetics and Molecular Biology(all)
- Cell Biology